Capital International Investors Amends Zentalis Pharma Stake

TL;DR

**Capital International Investors updated their Zentalis Pharma stake, watch for potential market reaction.**

AI Summary

Capital International Investors, a major institutional investor, filed an amended SC 13G/A on February 9, 2024, indicating a change in their ownership of Zentalis Pharmaceuticals, Inc. common stock as of December 29, 2023. This filing updates their previous disclosure, signaling that their stake in Zentalis has likely shifted, which is important for investors to track as large institutional movements can influence stock perception and liquidity.

Why It Matters

Large institutional investor movements can signal confidence or concern in a company, potentially influencing other investors and the stock's price.

Risk Assessment

Risk Level: low — This filing is an update to an existing ownership disclosure, not a new, unexpected event, making it a low-risk informational update.

Analyst Insight

Investors should monitor subsequent filings from Capital International Investors or Zentalis Pharmaceuticals to understand the exact nature and magnitude of the ownership change, as this filing only indicates an amendment, not the specific change in share count or percentage.

Key Players & Entities

• Capital International Investors (company) — the reporting person and institutional investor
• Zentalis Pharmaceuticals, Inc. (company) — the subject company whose stock is being reported
• December 29, 2023 (date) — the date of the event requiring the filing
• February 9, 2024 (date) — the filing date of the SC 13G/A

FAQ

Filing Documents

• SEC13G_Filing.htm (SC 13G/A) — 16KB
• 0001422848-24-000149.txt ( ) — 18KB

From the Filing

SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 ) * Zentalis Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 98943L107 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.) CUSIP No. 98943L107 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Capital International Investors 95-1411037 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 2,819,664 6. SHARED VOTING POWER 0 7. SOLE DISPOSITIVE POWER 2,819,664 8. SHARED DISPOSITIVE POWER 0 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,819,664 Beneficial ownership disclaimed pursuant to Rule 13d-4 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.0% 12. TYPE OF REPORTING PERSON IA Item 1. (a) Name of Issuer Zentalis Pharmaceuticals, Inc. (b) Address of Issuer's Principal Executive Offices 1359 Broadway, Suite 801, New York, NY 10018 Item 2. (a) Name of Person Filing Capital International Investors (b) Address of Principal Business Office or, if None, Residence 333 South Hope Street, 55th Fl, Los Angeles, CA 90071 (c) Citizenship N/A (d) Title of Class of Securities Common Stock (e) CUSIP Number 98943L107 Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [X] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F); (g) [ ] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G); (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J). Item 4. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount Beneficially Owned: 2,819,664 ** (b) Percent of Class: 4.0% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote 2,819,664 (ii) shared power to vote or to direct the vote 0 (iii) sole power to dispose or to direct the disposition of 2,819,664 (iv) shared power to dispose or to direct the disposition of 0 **Capital International Investors ("CII") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CII's divisions of each of the investment management entities collectively provide investment management services under the name "Capital International Investors." CII is deemed to be the beneficial owner of 2,819,664 shares or 4.0% of the 70,765,771 shares believed to be outstanding. Item 5. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the benefic

View Full Filing

View this SC 13G/A filing on SEC EDGAR